Experience

Davis Polk advised the initial purchasers on a Rule 144A and Regulation S reopening of $50 million aggregate principal amount of 7.500% senior secured notes due 2028 of AI…

Davis Polk advised The Royal Bank of Scotland Group plc, a public limited company incorporated under the laws of Scotland, in connection with its SEC-registered shelf takedown of $1.25…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by Textron Inc. of $300 million aggregate principal amount of its 3.900%…

Davis Polk advised the forward purchasers and forward sellers in connection with an at-the-market forward underwriting program for the offer and sale of shares of common stock of AvalonBay…

Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…

Davis Polk advised the initial purchasers in connection with the offering by Sociedad Química y Minera de Chile S.A. of $450 million aggregate principal amount of its 4.250% notes due 2029…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares representing 9,019,608 ordinary shares of the company. The ADSs…

Davis Polk advised the representative of the initial purchasers in connection with Rule 144A/Regulation S offerings by JBS USA Lux S.A., JBS USA Food Company and JBS USA Finance, Inc…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…

Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…